Samsung Biologics

1 trends tracked about this subject — the full history, oldest to newest below.

◼ Archived Business 🔮 fades

Samsung Biologics is pursuing a $1.8 billion all-cash acquisition of Swiss CDMO PolyPeptide to expand its global peptide manufacturing network.

11 sources 13 articles v 11 46d ago

\n \n \n

\n \n \n \n